CDKN2A and brain neoplasm: CDKN2A loss has been previously reported in ST ependymoma and is known to be an indicator of adverse prognosis in RELA-fused ependymomas [25] and other brain tumors such as IDH-mutated anaplastic astrocytoma [26].